Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Neuroblastoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Camurati-Engelmann Syndrome 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

Rituximab 14Bortezomib 9Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Filgrastim 5temsirolimus 4tanespimycin 4alvocidib 4Magnetic Resonance Spectroscopy 4Indium 4Cyclophosphamide 4ibritumomab tiuxetan 3Vorinostat 3Sirolimus 3Carboplatin 3sargramostim 2oblimersen 2ibrutinib 2belinostat 2Radiotherapy 2Pharmacogenomic Testing 2Methotrexate 2MK 2206 2Lenalidomide 2Interleukin-12 Subunit p35 2Interferon-alpha 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cyclosporine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Waldenstrom Macroglobulinemia × Fenretinide × Clear all
NCT00288067 2014-10-06

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
32 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡